The European AI in antibody identification market is experiencing a considerable surge, driven primarily by increasing investments in biotechnology and a stronger focus on personalized medicine. Analysts anticipate important advancements in therapeutic antibody development utilizing artificial intelligence, particularly within fields like oncology